10.14.26 -- Your CDMO Can Make It, But Can Your Market Afford It?

How can manufacturers balance security, compliance, and supply continuity in controlled substance development and production?

Improving pediatric adherence requires age-appropriate formulations, taste-masking, and swallowability strategies. Regulatory insights help overcome barriers and support more effective therapies.

Discover how continuous manufacturing, AI-driven digital twins, and advanced tooling materials are transforming tablet compression to boost quality and cut operational costs in pharmaceutical production.

Hidden gaps in process maturity and organizational alignment can derail development. Assimilate how to identify risks early and improve readiness for key milestones.

This session presents a risk-based framework for high-potency micronization, illustrated through a practical case study that spans development to commercial scale.

When an oral liquid formulation of crizotinib failed pediatric trials due to intolerable taste and irritation, a multiparticulate approach offered a technically demanding but viable path forward.

Gain insight into a coordinated, around-the-clock approach that demonstrates how packaging efficiency can keep pace with urgent pharmaceutical launches and tight commercialization timelines.

Choosing the right packaging partner for your probiotic may be the most crucial step to ensuring your product is safe and potent when it reaches the consumer.

Explore strategies to solve solubility and permeability challenges, boost oral bioavailability, and ensure consistent absorption — reducing risk and unlocking complex molecules.

Review the crucial selection of the optimal solid form in  carefully achieving successful jet milling of APIs designed specifically for pulmonary administration through the pulmonary route.